Vitamin D3 shows promise for ulcerative colitis in new trial
NCT ID NCT07269223
First seen Jan 10, 2026 · Last updated Jun 18, 2026 · Updated 27 times
Summary
This study tests whether taking vitamin D3 supplements can lower inflammation in people with moderate ulcerative colitis. Sixty adults aged 20-40 will either get standard care plus a placebo or standard care plus a high dose of vitamin D3 every two weeks for 12 weeks. Researchers will measure changes in blood and stool markers of inflammation and track disease activity and quality of life. The goal is to see if vitamin D3 can be a helpful add-on treatment for managing this chronic condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Veterinary & Animal Sciences, Lahore
RECRUITINGLahore, Punjab Province, 54000, Pakistan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.